{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000117","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.709530+00:00","generated_at":"2026-05-16T22:22:02.065060+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nurix appoints former Pfizer oncology chief Roger Dansey to board","bullets":["Dr. Dansey appointed effective Nov 6, 2025, as Class III director and member of Clinical and Commercialization Committee.","Former Chief Development Officer and Chief Oncology Officer at Pfizer; previously CMO and interim CEO of Seagen.","Initial stock option grant of 50,000 shares, vesting monthly over three years; pro rata annual retainer of $50,000.","Dansey brings experience from leading Keytruda development at Merck and Xgeva at Amgen."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000117","json":"https://secwatch.observer/filing/0001549595-25-000117.json","markdown":"https://secwatch.observer/filing/0001549595-25-000117.md","text":"https://secwatch.observer/filing/0001549595-25-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000117/0001549595-25-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000117/nrix-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:22:02.065060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}